Menu ausklappen

Bitte beachten: An Rosenmontag (04.03.2019) ist die Praxis geschlossen.

Proteases (uPA/PAI-1)

Analysis of prognostic proteins (uPa and PAI-1) from breast cancer tissue extracts

uPA and PAI-1 are parts of the plasminogen-activator system. The plasminogen-activator system is a complex system with many partners and molecular interactions that is not only relevant to fibrinolysis, but also plays a significant role in cell motility, angiogenesis, wound healing, tumor cell seeding, and metastasis. Raised uPA and/or PAI-1 markers can be found in aggressive tumors. Patients with high uPA/PAI-1 markers have a shortened recurrence free expectancy and an overall shortened life expectancy. The clinical significance of uPA and PAI-1 is at the highest level of evidence (LOE). Additionally, uPA and PAI-1 are used as predictive factors for the response to chemotherapy. The German AGO Breast Committee (“Arbeitsgemeinschaft gynäkologischer Onkologen“) recommends both bio markers for routine use in lymph node negative breast cancer patients.

Test Requirements:

Cryopreserved tissue must be available. Tissue collected in fine-needle aspiration biopsies usually does not suffice. However, the amount of tissue collected in vacuum assisted biopsies and punch biopsies most commonly does. The assay cannot be carried out on formalin-fixed paraffin-embedded tissue blocks. If the test requirements for the uPA/PAI-1-determination cannot be met, we recommend our PANTHER-chip test. It determines the activity of the associated genes PLAU (for uPA) and SERPINE1 (for PAL-1).

In special cases, in which no fresh tumor tissue can be provided, we can also carry out the test by drawing on circulating tumor cells gathered from peripheral blood.

Duration of Testing

The result will be available after a week at the latest.


In all of Germany, the lead time is 24 hours before a planned procedure. A single call will do, just ring us at 0211 4477 4388 (landline) or 0171 784 989 4 (cell). We will take care of the entire logistic process for you.

Risk Calculation

Adjuvant chemotherapy for lymph-node negative breast cancer in relation to classical risk groups and impact of uPA/PAI-1 testing.

We are happy to consult you in finding the right treatment!